Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1840-1843

  Noren T ^a   Akerlund T ^c   Wullt, M ^b   Burman, L G ^c   Unemo, M ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID;

ARTICLE; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE; CODON; CONTROLLED STUDY; DIARRHEA; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; FUSIDIC ACID; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PEPTIDE ELONGATION FACTOR G;

EID: 34248367707     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01283-06     Document Type: Article

References (29)

1. Besier, S., A. Ludwig, V. Brade, and T. A. Wichelhaus. 2003. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol. Microbiol. 47:463-469.
2. Brown, E. M., and P. Thomas. 2002. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 359:803.
3. Bruggemann, H., S. Baumer, W. F. Fricke. A. Wiezer, H. Liesegang, I. Decker, C. Herzberg, R. Martinez-Arias, R. Merkl, A. Henne, and G. Gottschalk. 2003. The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc. Natl. Acad. Sci. USA 100:1316-1321.
4. Burdon, D. W., J. D. Brown, D. J. Youngs, Y. Arabi. N. Shinagawa, J. Alexander-Williams, M. R. Keighley, and R. H. George. 1979. Antibiotic susceptibility of Clostridium difficile. J. Antimicrob. Chemother. 5:307-310.
5. Cronberg, S., B. Castor, and A. Thoren. 1984. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 12: 276-279.
6. Fernandez, A., G. Anand, and F. Friedenberg. 2004. Factors associated with failure of metronidazole in Clostridium difficile- associated disease. J. Clin. Gastroenterol. 38:414-418.
7. Godtfredsen, W., K. Roholt, and L. Tybring. 1962. Fucidin: a new orally active antibiotic. Lancet i:928-931.
8. Johanson, U., and D. Hughes. 1994. Fusidic acid-resistant mutants define three regions in elongation factor G of Salmonella typhimurium. Gene 143: 55-59.
9. Kunst, F., N. Ogasawara, I. Moszer, A. M. Albertini, G. Alloni, V. Azevedo, M. G. Bertero, P. Bessieres, A. Bolotin, S. Borchert, R. Borriss, L. Boursier, A. Brans, M. Braun, S. C. Brignell, S. Bron, S. Brouillet, C. V. Bruschi, B. Caldwell, V. Capuano, N. M. Carter, S. K. Choi, J. J. Codani, I. F. Connerton, A. Danchin, et al. 1997. The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature 390:249-256.
10. Laurberg, M., O. Kristensen, K. Martemyanov, A. T. Gudkov, I. Nagaev, D. Hughes, and A. Liljas. 2000. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J. Mol. Biol. 303:593-603.
11. Leroi, M. J., S. Siarakas, and T. Gottlieb. 2002. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur. J. Clin. Microbiol. Infect. Dis. 21:72-74.
12. Macvanin, M., J. Bjorkman, S. Eriksson, M. Rhen, D. I. Andersson, and D. Hughes. 2003. Fusidic acid-resistant mutants of Salmonella enterica serovar Typhimurium with low fitness in vivo are defective in RpoS induction. Antimicrob. Agents Chemother. 47:3743-3749.
13. Musher, D. M., S. Aslam, N. Logan, S. Nallacheru, I. Bhaila, F. Borchert, and R. J. Hamill. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
14. Nagaev, I., J. Bjorkman, D. I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40:433-439.
15. Nolling, J., G. Breton, M. V. Omelchenko, K. S. Makarova, Q. Zeng, R. Gibson, H. M. Lee, J. Dubois, D. Qiu, J. Hitti, Y. I. Wolf, R. L. Tatusov, F. Sabathe, L. Doucette-Stamm, P. Soucaille, M. J. Daly, G. N. Bennett, E. V. Koonin, and D. R. Smith. 2001. Genome sequence and comparative analysis of the solvent-producing bacterium Clostridium acetobutylicum. J. Bacteriol. 183:4823-4838.
16. Norén, T., M. Wullt, T. Åkerlund, E. Bäck, I. Odenholt, and L. G. Burman. 2006. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob. Agents Chemother. 50:3028-3032.
17. Norén, T., T. Åkerlund, E. Bäck, L. Sjöberg, I. Persson, I. Alriksson, and L. G. Burman. 2004. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J. Clin. Microbiol. 42:3635-3643.
18. O'Neill, A. J., J. M. Bostock, A. M. Moita, and I. Chopra. 2002. Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. J. Antimicrob. Chemother. 50:839-848.
19. O'Neill, A. J., A. R. Larsen, A. S. Henriksen, and I. Chopra. 2004. A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob. Agents Chemother. 48:3594-3597.
20. Osterlund, A., T. Eden, B. Olsson-Liljequist, S. Haeggman, and G. Kahlmeter. 2002. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand. J. Infect. Dis. 34:729-734.
21. Peeters, K. A., E. M. Mascini, and C. J. Sanders. 2004. Resistance of Staphylococcus aureus to fusidic acid. Int. J. Dermatol. 43:235-236.
22. Projan, S. J. 2000. Antibiotic resistance in the staphylococci. In U. A. Fischetti, R. P. Norvich, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. American Society for Microbiology, Washington, DC.
23. Rasko, D. A., J. Ravel, O. A. Okstad, E. Helgason, R. Z. Cer, L. Jiang, K. A. Shores, D. E. Fouts, N. J. Tourasse, S. V. Angiuoli, J. Kolonay, W. C. Nelson, A. B. Kolsto, C. M. Fraser, and T. D. Read. 2004. The genome sequence of Bacillus cereus ATCC 10987 reveals metabolic adaptations and a large plasmid related to Bacillus anthracis pXO1. Nucleic Acids Res. 32:977-988.
24. Reeves, D. S. 1987. The pharmacokinetics of fusidic acid. J. Antimicrob. Chemother. 20:467-476.
25. Shimizu, T., K. Ohtani, H. Hirakawa, K. Ohshima, A. Yamashita, T. Shiba, N. Ogasawara, M. Hattori, S. Kuhara, and H. Hayashi. 2002. Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater. Proc. Natl. Acad. Sci. USA 99:996-1001.
26. Unemo, M., P. Olcen, J. Albert, and H. Fredlund. 2003. Comparison of serologic and genetic porB-based typing of Neisseria gonorrhoeae: consequences for future characterization. J. Clin. Microbiol. 41:4141-4147.
27. Wenisch, C., B. Parschalk, M. Hasenhundl, A. M. Hirschl, and W. Graninger. 1996. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22:813-818.
28. Weston, V. C., T. C. Boswell, R. G. Finch, and W. Perkins. 2002. Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use. BMJ 324:1394.
29. Wullt, M., and I. Odenholt. 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 54:211-216.